A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.

Abstract:

BACKGROUND:There is currently limited information regarding the prognostic ability of the dNLR-PNI (the combination of the derived neutrophil-to-lymphocyte ratio [dNLR] and prognostic nutritional index [PNI]) for hepatocellular carcinoma (HCC). This study aimed to assess the predictive ability of the dNLR-PNI in patients with intermediate-to-advanced HCC after transarterial chemoembolization (TACE). METHODS:A total of 761 HCC patients were enrolled in the study. The dNLR-PNI was retrospectively calculated in these patients, as follows: patients with both an elevated dNLR and a decreased PNI, as determined using the cutoffs obtained from receiver operating characteristic curve analysis, were allocated a score of 2, while patients showing one or neither of these alterations were allocated a score of 1 or 0, respectively. RESULTS:During the follow-up period, 562 patients died. Multivariate analysis suggested that elevated total bilirubin, Barcelona Clinic Liver Cancer C stage, repeated TACE, and dNLR-PNI were independently associated with unsatisfactory overall survival. The median survival times of patients with a dNLR-PNI of 0, 1, and 2 were 31.0 (95% confidence interval [CI] 22.5-39.5), 16.0 (95% CI 12.2-19.7) and 6.0 (95% CI 4.8-7.2) months, respectively (P < 0.001). CONCLUSIONS:The dNLR-PNI can predict the survival outcomes of intermediate-to-advanced HCC patients undergoing TACE, and should be further evaluated as a prognostic marker for who are to undergo TACE treatment.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Liu C,Li L,Lu WS,Du H,Yan LN,Wen TF,Wei WR,Jiang L,Xu MQ

doi

10.1186/s12885-018-4121-3

subject

Has Abstract

pub_date

2018-02-21 00:00:00

pages

216

issue

1

issn

1471-2407

pii

10.1186/s12885-018-4121-3

journal_volume

18

pub_type

杂志文章
  • Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.

    abstract:BACKGROUND:Plasminogen activator inhibitor 1 (PAI-1) overexpression is an important prognostic and predictive biomarker in human breast cancer. SERBP1, a protein that is supposed to regulate the stability of PAI-1 mRNA, may play a role in gynaecological cancers as well, since upregulation of SERBP1 was described in ova...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-597

    authors: Serce NB,Boesl A,Klaman I,von Serényi S,Noetzel E,Press MF,Dimmler A,Hartmann A,Sehouli J,Knuechel R,Beckmann MW,Fasching PA,Dahl E

    更新日期:2012-12-13 00:00:00

  • Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.

    abstract:BACKGROUND:Biannual ultrasound (US)-with or without alpha-fetoprotein (AFP)-is recommended by current guidelines for the surveillance of hepatocellular carcinoma (HCC). However, the inadequate sensitivity of US has been a concern. Magnetic resonance imaging (MRI) is known to have high sensitivity in detecting hepatic m...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1186/s12885-018-4827-2

    authors: An C,Kim DY,Choi JY,Han KH,Roh YH,Kim MJ

    更新日期:2018-09-24 00:00:00

  • Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.

    abstract:BACKGROUND:Following resection of liver metastases from colorectal cancer, 5-year survivals are reportedly 30 - 39%. It can be assumed that this clinical situation represents systemic disease. Therefore, it is postulated that systemic chemotherapy would improve outcomes, particularly in those whose disease is sensitive...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1186/1471-2407-4-32

    authors: Bathe OF,Dowden S,Sutherland F,Dixon E,Butts C,Bigam D,Walley B,Ruether D,Ernst S

    更新日期:2004-07-10 00:00:00

  • Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.

    abstract:BACKGROUND:Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta®, Amgen) with sustained release properties. This is a randomized, comparative, ...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-019-5329-6

    authors: Kahan Z,Grecea D,Smakal M,Tjulandin S,Bondarenko I,Perjesi L,Illes A,Horvat-Karajz K,Aradi I

    更新日期:2019-02-06 00:00:00

  • Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma.

    abstract:BACKGROUND:Early diagnosis is important for the timely treatment of gallbladder carcinoma (GBC) patients and may lead to increased survival outcomes. Here, we have applied serological proteome analysis (SERPA), an immunoproteomics approach, for the detection of 'tumor-associated antigens (TAAs) that elicit humoral resp...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07676-6

    authors: Akhtar J,Priya R,Jain V,Sakhuja P,Agarwal AK,Goyal S,Polisetty RV,Sirdeshmukh R,Kar S,Gautam P

    更新日期:2020-12-01 00:00:00

  • Germline mutation in the RAD51B gene confers predisposition to breast cancer.

    abstract:BACKGROUND:Most currently known breast cancer predisposition genes play a role in DNA repair by homologous recombination. Recent studies conducted on RAD51 paralogs, involved in the same DNA repair pathway, have identified rare germline mutations conferring breast and/or ovarian cancer predisposition in the RAD51C, RAD...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-484

    authors: Golmard L,Caux-Moncoutier V,Davy G,Al Ageeli E,Poirot B,Tirapo C,Michaux D,Barbaroux C,d'Enghien CD,Nicolas A,Castéra L,Sastre-Garau X,Stern MH,Houdayer C,Stoppa-Lyonnet D

    更新日期:2013-10-19 00:00:00

  • ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

    abstract:BACKGROUND:Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of n...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-016-2564-y

    authors: Hoeppner J,Lordick F,Brunner T,Glatz T,Bronsert P,Röthling N,Schmoor C,Lorenz D,Ell C,Hopt UT,Siewert JR

    更新日期:2016-07-19 00:00:00

  • Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.

    abstract:BACKGROUND:Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote cancer progression including cell survival, metastasis, and chemoresistance. The main objective of ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07761-w

    authors: Oo KK,Kamolhan T,Soni A,Thongchot S,Mitrpant C,O-Charoenrat P,Thuwajit C,Thuwajit P

    更新日期:2021-01-14 00:00:00

  • Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.

    abstract:BACKGROUND:To compare the survival outcomes and acute toxicities of concurrent chemoradiotherapy (CCRT), induction chemotherapy (IC) plus radiotherapy (RT), and IC plus CCRT in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiotherapy (IMRT). METHODS:Patients w...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1768-x

    authors: Li WF,Li YQ,Chen L,Zhang Y,Guo R,Zhang F,Peng H,Sun Y,Ma J

    更新日期:2015-10-27 00:00:00

  • Internet-based perioperative exercise program in patients with Barrett's carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial.

    abstract:BACKGROUND:Patients undergoing surgery for esophageal cancer have a high risk for postoperative deterioration of lung function and pulmonary complications. This is partly due to one-lung ventilation during thoracotomy. This often accounts for prolonged stay on intensive care units, delayed postoperative reconvalescence...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-017-3400-8

    authors: Pfirrmann D,Tug S,Brosteanu O,Mehdorn M,Busse M,Grimminger PP,Lordick F,Glatz T,Hoeppner J,Lang H,Simon P,Gockel I

    更新日期:2017-06-14 00:00:00

  • Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling.

    abstract:BACKGROUND:Cell migration and invasion are essential processes for metastatic dissemination of cancer cells. Significant progress has been made in developing new therapies against oncogenic signaling to eliminate cancer cells and shrink tumors. However, inherent heterogeneity and treatment-induced adaptation to drugs c...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-6479-2

    authors: Shahi Thakuri P,Gupta M,Singh S,Joshi R,Glasgow E,Lekan A,Agarwal S,Luker GD,Tavana H

    更新日期:2020-01-02 00:00:00

  • Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

    abstract:BACKGROUND:The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with renal cell carcinoma (RCC). METHODS:EZH2 protein expression in RC...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-524

    authors: Wagener N,Macher-Goeppinger S,Pritsch M,Hüsing J,Hoppe-Seyler K,Schirmacher P,Pfitzenmaier J,Haferkamp A,Hoppe-Seyler F,Hohenfellner M

    更新日期:2010-10-04 00:00:00

  • Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

    abstract:BACKGROUND:Suppressor of cytokine signaling (SOCS) proteins comprise a protein family, which has initially been described as STAT induced inhibitors of the Jak/Stat pathway. Recent in vivo and in vitro studies suggest that SOCS proteins are also implicated in cancer. The STAT5 induced IGF-I acts as an endocrine and par...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1186/1471-2407-7-136

    authors: Haffner MC,Petridou B,Peyrat JP,Révillion F,Müller-Holzner E,Daxenbichler G,Marth C,Doppler W

    更新日期:2007-07-25 00:00:00

  • P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.

    abstract:BACKGROUND:High grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) with a Ki67 proliferation index > 20%, include well-differentiated tumours grade 3 (NET G3) and poorly differentiated (PD) neuroendocrine carcinomas (NEC). Abnormal p53-expression is a feature of PD tumours, while expression of chromogran...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-6498-z

    authors: Nielsen K,Binderup T,Langer SW,Kjaer A,Knigge P,Grøndahl V,Melchior L,Federspiel B,Knigge U

    更新日期:2020-01-10 00:00:00

  • Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.

    abstract:BACKGROUND:Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for breast cancer care but mostly focused on HER2-negative subtypes. Preclinical researches involving this drug mostly concern Triple Negative Breast Cancer (TNBC) murine models. Here, we explored the therapeutic...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1540-2

    authors: Thézé B,Bernards N,Beynel A,Bouet S,Kuhnast B,Buvat I,Tavitian B,Boisgard R

    更新日期:2015-07-22 00:00:00

  • Projecting productivity losses for cancer-related mortality 2011 - 2030.

    abstract:BACKGROUND:When individuals stop working due to cancer this represents a loss to society - the loss of productivity. The aim of this analysis was to estimate productivity losses associated with premature mortality from all adult cancers and from the 20 highest mortality adult cancers in Ireland in 2011, and project the...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2854-4

    authors: Pearce A,Bradley C,Hanly P,O'Neill C,Thomas AA,Molcho M,Sharp L

    更新日期:2016-10-18 00:00:00

  • Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas.

    abstract:BACKGROUND:The association between colorectal cancer (CRC) and smoking has not been consistent. Incomplete smoking history and association to a specific subset of CRC tumors have been proposed as explanations. The adenomatous polyposis coli (APC) gene has been reported to have a "gatekeeper" function in the colonic muc...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-71

    authors: Sarebø M,Skjelbred CF,Breistein R,Lothe IM,Hagen PC,Bock G,Hansteen IL,Kure EH

    更新日期:2006-03-17 00:00:00

  • (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

    abstract:BACKGROUND:Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side e...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2060-4

    authors: Schneider TC,Kapiteijn E,van Wezel T,Smit JWA,van der Hoeven JJM,Morreau H

    更新日期:2016-01-19 00:00:00

  • Selective microdochectomy after ductoscopic wire marking in women with pathological nipple discharge.

    abstract:BACKGROUND:To investigate the diagnostic reliability of selective microdochectomy after direct ductoscopic wire marking of suspect lesions in patients with pathological nipple discharge. METHODS:Selective microdochectomy due to pathological discharge was performed in 33 patients with mean age of 51.7 years. Ductoscope...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-151

    authors: Hahn M,Fehm T,Solomayer EF,Siegmann KC,Hengstmann AS,Wallwiener D,Ohlinger R

    更新日期:2009-05-17 00:00:00

  • Cervical cancer screening in rural Ethiopia: a cross- sectional knowledge, attitude and practice study.

    abstract:BACKGROUND:Cervical cancer is the fourth most common cancer among women worldwide. Sub- Saharan Africa has a high incidence, prevalence and mortality due to shortage and underutilization of screening facilities. This study aims to assess knowledge and attitude towards cervical cancer and its prevention, as well as prac...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07060-4

    authors: Ruddies F,Gizaw M,Teka B,Thies S,Wienke A,Kaufmann AM,Abebe T,Addissie A,Kantelhardt EJ

    更新日期:2020-06-17 00:00:00

  • Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR).

    abstract:BACKGROUND:Recent reports indicate the existence of breast cancer cells expressing very high levels of the Arylhydrocarbon receptor (AhR), a ubiquitous intracellular receptor best known for mediating toxic action of dioxin and related pollutants. Positive correlation between the degree of AhR overexpression and states ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-234

    authors: Wong PS,Li W,Vogel CF,Matsumura F

    更新日期:2009-07-15 00:00:00

  • Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.

    abstract:BACKGROUND:Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials investigating immunotherapies in metastatic melanoma. Since information on pre-existi...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4051-0

    authors: Ma Q,Shilkrut M,Zhao Z,Li M,Batty N,Barber B

    更新日期:2018-02-06 00:00:00

  • Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.

    abstract:BACKGROUND:Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of different patients to everolimus may ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5668-3

    authors: Yi Z,Ma F,Liu B,Guan X,Li L,Li C,Qian H,Xu B

    更新日期:2019-05-14 00:00:00

  • The acceptability of high resolution anoscopy examination in patients attending a tertiary referral centre.

    abstract:BACKGROUND:High resolution anoscopy (HRA) examination is regarded as the best method for the management of anal high grade squamous intraepithelial lesions to prevent anal squamous carcinoma. However, little is known about the acceptability of this procedure. This analysis looks at patient experience of HRA examination...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4475-6

    authors: De-Masi A,Davis E,Cuming T,Chindawi N,Pesola F,Cappello C,Chambers S,Bowring J,Rosenthal AN,Sasieni P,Nathan M

    更新日期:2018-05-11 00:00:00

  • Btbd7 contributes to reduced E-cadherin expression and predicts poor prognosis in non-small cell lung cancer.

    abstract:BACKGROUND:Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its func...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-704

    authors: Fan C,Miao Y,Zhang X,Liu D,Jiang G,Lin X,Han Q,Luan L,Xu Z,Wang E

    更新日期:2014-09-24 00:00:00

  • Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

    abstract:BACKGROUND:Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-017-3803-6

    authors: Seymour JF,Döhner H,Butrym A,Wierzbowska A,Selleslag D,Jang JH,Kumar R,Cavenagh J,Schuh AC,Candoni A,Récher C,Sandhu I,Del Castillo TB,Al-Ali HK,Falantes J,Stone RM,Minden MD,Weaver J,Songer S,Beach CL,Dombret H

    更新日期:2017-12-14 00:00:00

  • Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

    abstract:BACKGROUND:An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and complex therapy. It requests substantial upfront investments from the hosp...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4788-5

    authors: Retèl VP,Steuten LMG,Geukes Foppen MH,Mewes JC,Lindenberg MA,Haanen JBAG,van Harten WH

    更新日期:2018-09-15 00:00:00

  • Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

    abstract:BACKGROUND:Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their molecular transducers were analysed in terms of mutations, amplifications and over-expression in a...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-631

    authors: Pignochino Y,Sarotto I,Peraldo-Neia C,Penachioni JY,Cavalloni G,Migliardi G,Casorzo L,Chiorino G,Risio M,Bardelli A,Aglietta M,Leone F

    更新日期:2010-11-18 00:00:00

  • Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model.

    abstract:BACKGROUND:Gastric cancer is a considerable burden for worldwide patients. And diffuse gastric cancer is the most insidious subgroup with poor survival. The phenotypic characterization of the diffuse gastric cancer cell line can be useful for gastric cancer researchers. In this article, we aimed to characterize the dif...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-06814-4

    authors: Yoon SJ,Park J,Shin Y,Choi Y,Park SW,Kang SG,Son HY,Huh YM

    更新日期:2020-04-15 00:00:00

  • Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment.

    abstract:BACKGROUND:The aim of this study was to determine influence of prognostic factors in addition to UICC staging systems, on cancer-specific and overall survival rates for patients with colorectal cancer (CRC) undergoing surgical treatment. METHODS:Between January 1996 and December 2006, a total of 1367 CRC patients who ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-288

    authors: Sun LC,Chu KS,Cheng SC,Lu CY,Kuo CH,Hsieh JS,Shih YL,Chang SJ,Wang JY

    更新日期:2009-08-20 00:00:00